CA2389626A1 - Methode de formation de micropores dans la peau - Google Patents
Methode de formation de micropores dans la peau Download PDFInfo
- Publication number
- CA2389626A1 CA2389626A1 CA002389626A CA2389626A CA2389626A1 CA 2389626 A1 CA2389626 A1 CA 2389626A1 CA 002389626 A CA002389626 A CA 002389626A CA 2389626 A CA2389626 A CA 2389626A CA 2389626 A1 CA2389626 A1 CA 2389626A1
- Authority
- CA
- Canada
- Prior art keywords
- stratum corneum
- sonic
- range
- ultrasonic radiation
- surface area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 123
- 230000005855 radiation Effects 0.000 claims abstract description 52
- 239000011148 porous material Substances 0.000 claims abstract description 37
- 239000000463 material Substances 0.000 claims abstract description 23
- 238000012546 transfer Methods 0.000 claims abstract description 19
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 15
- 238000002604 ultrasonography Methods 0.000 claims description 81
- 229940079593 drug Drugs 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- -1 anti-migraine drugs Substances 0.000 claims description 11
- 230000003637 steroidlike Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000002269 analeptic agent Substances 0.000 claims description 4
- 229940035676 analgesics Drugs 0.000 claims description 4
- 229940035674 anesthetics Drugs 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 4
- 230000003262 anti-osteoporosis Effects 0.000 claims description 4
- 230000000648 anti-parkinson Effects 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 239000000729 antidote Substances 0.000 claims description 4
- 229940075522 antidotes Drugs 0.000 claims description 4
- 229940125715 antihistaminic agent Drugs 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 229940124433 antimigraine drug Drugs 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940034982 antineoplastic agent Drugs 0.000 claims description 4
- 239000000939 antiparkinson agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 229940121357 antivirals Drugs 0.000 claims description 4
- 239000002830 appetite depressant Substances 0.000 claims description 4
- 229960000074 biopharmaceutical Drugs 0.000 claims description 4
- 229940125692 cardiovascular agent Drugs 0.000 claims description 4
- 239000002327 cardiovascular agent Substances 0.000 claims description 4
- 239000003433 contraceptive agent Substances 0.000 claims description 4
- 229940124558 contraceptive agent Drugs 0.000 claims description 4
- 229940000033 dermatological agent Drugs 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003866 digestant Substances 0.000 claims description 4
- 239000003193 general anesthetic agent Substances 0.000 claims description 4
- 229940124563 hair growth stimulant Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 4
- 229940035363 muscle relaxants Drugs 0.000 claims description 4
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- 239000003887 narcotic antagonist Substances 0.000 claims description 4
- 229940001470 psychoactive drug Drugs 0.000 claims description 4
- 239000004089 psychotropic agent Substances 0.000 claims description 4
- 230000000506 psychotropic effect Effects 0.000 claims description 4
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 32
- 239000000243 solution Substances 0.000 description 16
- 210000002615 epidermis Anatomy 0.000 description 13
- 230000004907 flux Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 230000037317 transdermal delivery Effects 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 3
- 239000011449 brick Substances 0.000 description 3
- 238000000942 confocal micrograph Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 229910001006 Constantan Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- ZMRUPTIKESYGQW-UHFFFAOYSA-N propranolol hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 ZMRUPTIKESYGQW-UHFFFAOYSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
Abstract
Une méthode de formation de pores (600) dans la stratum corneum (210) consiste à appliquer une matière aqueuse (123) sur une zone de surface de la stratum corneum puis à appliquer un rayonnement sonore et/ou ultrasonore (112) à ladite matière aqueuse, dans laquelle ledit rayonnement sonore et/ou ultrasonore a une fréquence dans la gamme de 10 KHz et 5 MHz et est appliqué à une intensité, pendant une durée, et à une distance de ladite zone de surface de la stratum corneum efficace pour produire des bulles de cavitation (500) sur ladite zone de surface de la stratum cornenum, dans laquelle lesdites bulles de cavitation s'écrasent et transfèrent leur énergie dans la stratum corneum engendrant la formation de pores. Des molécules de grande taille ( > 500Da) dissoutes dans la matière aqueuse peuvent être transférées à travers ces pores et à travers la stratum corneum, puis atteindre les vaisseaux sanguins à des débits convenant à des applications thérapeutiques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16314699P | 1999-11-02 | 1999-11-02 | |
| US60/163,146 | 1999-11-02 | ||
| PCT/US2000/041754 WO2001032232A2 (fr) | 1999-11-02 | 2000-11-01 | Methode de formation de micropores dans la peau |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2389626A1 true CA2389626A1 (fr) | 2001-05-10 |
Family
ID=22588686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002389626A Abandoned CA2389626A1 (fr) | 1999-11-02 | 2000-11-01 | Methode de formation de micropores dans la peau |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2004520852A (fr) |
| AU (1) | AU3791201A (fr) |
| CA (1) | CA2389626A1 (fr) |
| WO (1) | WO2001032232A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923897B2 (en) | 2005-07-04 | 2011-04-12 | Sonopore, Ltd. | Sonic fine-hole forming apparatus |
| GB0518273D0 (en) * | 2005-09-08 | 2005-10-19 | Univ Dundee | Apparatus and method for sonoporation |
| KR102066046B1 (ko) | 2017-08-25 | 2020-01-14 | 주식회사 루트로닉 | Rf 에너지를 이용한 피부 치료장치 및 이를 이용한 피부 치료 방법 |
| US11648312B2 (en) * | 2017-12-22 | 2023-05-16 | Pierangela Giustetto | System for inducing sonoporation of a drug into cancer cells and method thereof |
| US20220008705A1 (en) * | 2018-10-31 | 2022-01-13 | Bioinfra Life Science Inc. | Method for increasing cell viability by using drug delivery system and ultrasound irradiation, and ultrasound irradiation apparatus using same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4767402A (en) * | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
| US5421816A (en) * | 1992-10-14 | 1995-06-06 | Endodermic Medical Technologies Company | Ultrasonic transdermal drug delivery system |
-
2000
- 2000-11-01 WO PCT/US2000/041754 patent/WO2001032232A2/fr active Application Filing
- 2000-11-01 JP JP2001534436A patent/JP2004520852A/ja active Pending
- 2000-11-01 AU AU37912/01A patent/AU3791201A/en not_active Abandoned
- 2000-11-01 CA CA002389626A patent/CA2389626A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU3791201A (en) | 2001-05-14 |
| WO2001032232A2 (fr) | 2001-05-10 |
| JP2004520852A (ja) | 2004-07-15 |
| WO2001032232A3 (fr) | 2002-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5833647A (en) | Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery | |
| ES2289192T3 (es) | Microporacion de tejido para suministro de agentes bioactivos. | |
| US5445611A (en) | Enhancement of transdermal delivery with ultrasound and chemical enhancers | |
| JP3554935B2 (ja) | マイクロキャリアーのエレクトロインコーポレーション法による経皮ドラッグ デリバリー | |
| Park et al. | Sonophoresis in transdermal drug deliverys | |
| Escobar-Chavez et al. | The use of sonophoresis in the administration of drugs throughout the skin | |
| US20030233085A1 (en) | Optimization of transcutaneous active permeation of compounds through the synergistic use of ultrasonically generated mechanical abrasion of the skin, chemical enhancers and simultaneous application of sonophoresis, iontophoresis, electroporation, mechanical vibrations and magnetophoresis through single application devices | |
| Nanda et al. | Current developments using emerging transdermal technologies in physical enhancement methods. | |
| AU725269B2 (en) | Enhanced transdermal transport using ultrasound | |
| DE69925461T2 (de) | Zielgerichtete abgabe von biologische-aktive medien | |
| WO1997013548A9 (fr) | Hydrogels ou lipogels a transfert de masse ameliore et destines a l'administration transdermique de medicaments | |
| US7232431B1 (en) | Intradermal incorporation of microparticles containing encapsulated drugs using low frequency ultrasound | |
| US7758561B2 (en) | Microporation of tissue for delivery of bioactive agents | |
| US6620123B1 (en) | Method and apparatus for producing homogenous cavitation to enhance transdermal transport | |
| Petchsangsai et al. | The combination of microneedles with electroporation and sonophoresis to enhance hydrophilic macromolecule skin penetration | |
| Zorec et al. | Ultrasound and electric pulses for transdermal drug delivery enhancement: Ex vivo assessment of methods with in vivo oriented experimental protocols | |
| US20030073949A1 (en) | Optimization of transcutaneous active permeation of compounds through the synergistic use of chemical enhancers and simultaneous application of sonophoresis, iontophoresis, electroporation, mechanical vibrations and magnetophoresis through a single application device | |
| KR20150008879A (ko) | 모낭성 전달을 위한 에너지 흡수 물질을 포함하는 조성물 및 방법 | |
| AU2006252145A1 (en) | Synergetic drug delivery device | |
| Zorec et al. | Combinations of nanovesicles and physical methods for enhanced transdermal delivery of a model hydrophilic drug | |
| US11266752B2 (en) | Methods of imaging and delivering therapeutic agents | |
| CA2389626A1 (fr) | Methode de formation de micropores dans la peau | |
| Goebel et al. | Dermal peptide delivery using colloidal carrier systems | |
| Sivakumar et al. | Transdermal drug delivery using ultrasound-theory, understanding and critical analysis | |
| WO2010017177A1 (fr) | Libération induite de manière ultrasonore à partir de vésicules polymères |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20040805 |